Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression
BackgroundAtezolizumab may provide clinical benefits to patients with advanced non-small cell lung cancer (NSCLC). However, the price of atezolizumab is relatively high, and its economic outcomes have remained unclear. In this study, we used two models to examine the cost-effectiveness of initial at...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2023-03-01
|
| coleção: | Frontiers in Oncology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1093469/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|